Enhancing sepsis biomarker development: key considerations from public and private perspectives
Methodological detailspublic-private workshop, expert opinion
- Public-private workshop
- Expert opinion
Recommendations
As issued by the authors
Better understanding of sepsis pathophysiology (trajectory from early inflammatory onset to late persisting immunosuppression) is mandatory to define the place of biomarkers
Develop time-resolved tests to characterise persistence of immunological dysfunction
Consider age-related differences between adult and paediatric septic patients
Biomarker-guided interventions (e.g. sTREM-1-guided Nangibotide, Adrenomedullin-guided Enibarcimab) appear promising but require further evaluation
Biomarker development requires a comprehensive multidisciplinary approach with the most advanced analytical tools, a platform merging scientific and commercial needs, and support of an expedited regulatory approval process
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →